tizanidine has been researched along with Muscle Spasm in 15 studies
tizanidine: RN given refers to parent cpd; structure
tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind trial tizanidine (DS 103-282: 5-Chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole), a new muscle relaxant, was compared with diazepam in twenty in-patients suffering from acute paravertebral muscle spasm." | 9.05 | Tizanidine (DS 103-282) in the treatment of acute paravertebral muscle spasm: a controlled trial comparing tizanidine and diazepam. ( Fryda-Kaurimsky, Z; Müller-Fassbender, H, 1981) |
| "Tizanidine is an imidazoline central alpha(2)-adrenoceptor agonist widely used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI)." | 8.84 | A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. ( Henney, HR; Kamen, L; Runyan, JD, 2008) |
| "Tizanidine hydrochloride (TIZ) is a skeletal muscle relaxant used to treat spasms, a sudden involuntary muscle contraction." | 8.02 | Derma roller mediated transdermal delivery of tizanidine invasomes for the management of skeletal muscle spasms. ( Brahmam, B; Chaudhari, P; Dsouza, L; Lewis, SA, 2021) |
| " The objective of this study was to evaluate the pharmacokinetic profile of tizanidine nasal spray and compare it to the profile of tizanidine oral tablets." | 6.78 | Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ( Cardì, F; Drago, F; Piazza, C; Salomone, S; Sinagra, T; Urso, V; Vitale, DC, 2013) |
| "Muscle spasm is an involuntary, painful contraction of muscles that interferes with the function and cause of muscular disorder." | 6.73 | Efficacy of thiocolchicoside in Indian patients suffering from low back pain associated with muscle spasm. ( Joshi, N; Soonawalla, DF, 2008) |
| " All efficacy parameters were evaluated by the physician/assessor, and the physician/prescriber was responsible for all dosage adjustments." | 6.67 | Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. ( Birnbaum, G; Carter, JL; Greenstein, J; Lublin, FD; Smith, C, 1994) |
| "Tizanidine is a well-tolerated and effective drug for symptomatic treatment of spasticity." | 6.67 | A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. ( , 1994) |
| "In a double-blind trial tizanidine (DS 103-282: 5-Chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole), a new muscle relaxant, was compared with diazepam in twenty in-patients suffering from acute paravertebral muscle spasm." | 5.05 | Tizanidine (DS 103-282) in the treatment of acute paravertebral muscle spasm: a controlled trial comparing tizanidine and diazepam. ( Fryda-Kaurimsky, Z; Müller-Fassbender, H, 1981) |
| "Tizanidine is an imidazoline central alpha(2)-adrenoceptor agonist widely used to manage spasticity secondary to conditions such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI)." | 4.84 | A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. ( Henney, HR; Kamen, L; Runyan, JD, 2008) |
| "Tizanidine hydrochloride (TIZ) is a skeletal muscle relaxant used to treat spasms, a sudden involuntary muscle contraction." | 4.02 | Derma roller mediated transdermal delivery of tizanidine invasomes for the management of skeletal muscle spasms. ( Brahmam, B; Chaudhari, P; Dsouza, L; Lewis, SA, 2021) |
| " The objective of this study was to evaluate the pharmacokinetic profile of tizanidine nasal spray and compare it to the profile of tizanidine oral tablets." | 2.78 | Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ( Cardì, F; Drago, F; Piazza, C; Salomone, S; Sinagra, T; Urso, V; Vitale, DC, 2013) |
| "Muscle spasm is an involuntary, painful contraction of muscles that interferes with the function and cause of muscular disorder." | 2.73 | Efficacy of thiocolchicoside in Indian patients suffering from low back pain associated with muscle spasm. ( Joshi, N; Soonawalla, DF, 2008) |
| " All efficacy parameters were evaluated by the physician/assessor, and the physician/prescriber was responsible for all dosage adjustments." | 2.67 | Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. ( Birnbaum, G; Carter, JL; Greenstein, J; Lublin, FD; Smith, C, 1994) |
| "Tizanidine was titrated to an optimized dosage in each patient to a maximum of 36 mg/d." | 2.67 | Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. ( Bugaresti, J; Martinez-Arizala, A; Nance, PW; Shellenberger, K; Sheremata, W, 1994) |
| "Tizanidine is a well-tolerated and effective drug for symptomatic treatment of spasticity." | 2.67 | A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. ( , 1994) |
| "The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol." | 2.48 | [Pharmacological treatment of spasticity in multiple sclerosis]. ( Heinzlef, O; Monteil-Roch, I, 2012) |
| " Treatment was started with DS 103-282 at a mean dosage of 7." | 1.26 | The spasmolytic properties of 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1,3-benzothiadiazole hydrochloride (DS 103-282): a pilot study. ( Lakke, JP; Sie, OG, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dsouza, L | 1 |
| Chaudhari, P | 1 |
| Brahmam, B | 1 |
| Lewis, SA | 1 |
| Vitale, DC | 1 |
| Piazza, C | 1 |
| Sinagra, T | 1 |
| Urso, V | 1 |
| Cardì, F | 1 |
| Drago, F | 1 |
| Salomone, S | 1 |
| Soonawalla, DF | 1 |
| Joshi, N | 1 |
| Heinzlef, O | 1 |
| Monteil-Roch, I | 1 |
| Zullino, DF | 1 |
| Eskenasy, AC | 1 |
| Beeson, J | 1 |
| Kamen, L | 1 |
| Henney, HR | 1 |
| Runyan, JD | 1 |
| Sie, OG | 1 |
| Lakke, JP | 1 |
| Fryda-Kaurimsky, Z | 1 |
| Müller-Fassbender, H | 1 |
| Meinck, HM | 1 |
| Ricker, K | 1 |
| Conrad, B | 1 |
| Smith, C | 1 |
| Birnbaum, G | 1 |
| Carter, JL | 1 |
| Greenstein, J | 1 |
| Lublin, FD | 1 |
| Nance, PW | 1 |
| Bugaresti, J | 1 |
| Shellenberger, K | 1 |
| Sheremata, W | 1 |
| Martinez-Arizala, A | 1 |
| Wallace, JD | 1 |
| Taricco, M | 1 |
| Adone, R | 1 |
| Pagliacci, C | 1 |
| Telaro, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Multicenter, Randomized Study to Assess the Efficacy and Safety of 0,5 mg Tizaspray® Administered Intranasally Versus Sirdalud® 2 mg Tablets, in Patients With Acute Low Back Pain[NCT02934061] | Phase 3 | 117 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for tizanidine and Muscle Spasm
| Article | Year |
|---|---|
[Pharmacological treatment of spasticity in multiple sclerosis].
Topics: Algorithms; Amines; Baclofen; Botulinum Toxins, Type A; Clonidine; Cyclohexanecarboxylic Acids; Dant | 2012 |
A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury.
Topics: Brain Injuries; Clonidine; Disease Progression; Drug Interactions; Female; Humans; Middle Aged; Mult | 2008 |
Summary of combined clinical analysis of controlled clinical trials with tizanidine.
Topics: Adult; Aged; Clonidine; Controlled Clinical Trials as Topic; Databases, Factual; Female; Humans; Mal | 1994 |
Pharmacological interventions for spasticity following spinal cord injury.
Topics: Baclofen; Clonidine; Dantrolene; Humans; Muscle Relaxants, Central; Parasympatholytics; Spasm; Spina | 2000 |
6 trials available for tizanidine and Muscle Spasm
| Article | Year |
|---|---|
Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm.
Topics: Administration, Intranasal; Adult; Animals; Area Under Curve; Biological Availability; Chromatograph | 2013 |
Efficacy of thiocolchicoside in Indian patients suffering from low back pain associated with muscle spasm.
Topics: Acute Disease; Administration, Oral; Adult; Analgesics; Clonidine; Colchicine; Female; Humans; India | 2008 |
Tizanidine (DS 103-282) in the treatment of acute paravertebral muscle spasm: a controlled trial comparing tizanidine and diazepam.
Topics: Acute Disease; Adult; Back Pain; Clinical Trials as Topic; Clonidine; Diazepam; Double-Blind Method; | 1981 |
Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
Topics: Adolescent; Adult; Aged; Clonidine; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple | 1994 |
Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group.
Topics: Activities of Daily Living; Administration, Oral; Adolescent; Adult; Aged; Clonidine; Female; Humans | 1994 |
A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Clonidine; Double-Blind Method; Female; Humans; | 1994 |
5 other studies available for tizanidine and Muscle Spasm
| Article | Year |
|---|---|
Derma roller mediated transdermal delivery of tizanidine invasomes for the management of skeletal muscle spasms.
Topics: Administration, Cutaneous; Animals; Clonidine; Drug Delivery Systems; Muscle, Skeletal; Rats; Spasm | 2021 |
High-dose tizanidine abuse.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Female; Humans; Muscle Relaxants, Central; Spasm; Subst | 2003 |
The spasmolytic properties of 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1,3-benzothiadiazole hydrochloride (DS 103-282): a pilot study.
Topics: Adult; Aged; Blood Pressure; Clonidine; Female; Humans; Male; Middle Aged; Parasympatholytics; Pilot | 1980 |
The stiff-man syndrome: new pathophysiological aspects from abnormal exteroceptive reflexes and the response to clomipramine, clonidine, and tizanidine.
Topics: Adult; Brain Stem; Clomipramine; Clonidine; Diazepam; Electromyography; Female; Humans; Muscle Rigid | 1984 |
[Current data on bipolar disorders, epilepsy and spasticity. 4. Neuro-Forum, Dresden].
Topics: Baclofen; Bipolar Disorder; Clonidine; Epilepsy; Female; Humans; Male; Muscle Relaxants, Central; Mu | 1999 |